Practical Guide,Aviptadil (RLF 100

The term RLF-100 peptide refers to aviptadil, a synthetic form of a naturally occurring human peptide known as Vasoactive Intestinal Peptide (VIP). This compound has garnered significant attention for its potential therapeutic applications, particularly in the treatment of respiratory conditions. RLF-100 (Aviptadil) is a formulation of synthetic human Vasoactive Intestinal Peptide, a molecule discovered in 1970 and naturally produced throughout the body.

RLF-100 is recognized as a peptide with potent antiproliferative properties. Its development has been spearheaded by companies like Relief Therapeutics Holdings and NeuroRx, with RLF-100 (aviptadil) being their lead drug candidate. The RLF-100 compound is essentially a patented formulation of synthetic 28 amino acid vasoactive intestinal polypeptide (VIP) analogue.

Clinical Trials and Therapeutic Applications of RLF-100

A significant focus of research and development for RLF-100 has been its efficacy in treating critical COVID-19 patients experiencing respiratory failure. Numerous clinical trials have been initiated to assess its impact. Specifically, RLF-100 is being studied in Phase II/III clinical trials to evaluate its effectiveness in this patient population. Furthermore, RLF-100 has received an Orphan Drug designation from the FDA, highlighting its potential for treating rare diseases.

The Search intent surrounding RLF-100 indicates a strong interest in its use for respiratory distress. The FDA grants inhaled IND use for RLF-100 to treat patients with moderate and severe COVID-19, aiming to prevent progression to respiratory complications. Studies have also explored the treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide, suggesting a broader application beyond COVID-19.

RLF-100 (Aviptadil) is currently conducting clinical trials of RLF-100 in patients with COVID-19 and has been investigated for its role in preventing COVID-19-related ARDS through inhaled administration. The compound is also under development for the potential treatment of other acute and chronic lung diseases, including pulmonary sarcoidosis and infectious acute respiratory conditions. Evidence suggests that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients.

The therapeutic strategy often involves RLF-100 is a formulation of vasoactive intestinal polypeptide, which targets alveolar type 2 cells in the lungs. This targeted approach is believed to contribute to its effectiveness in managing severe respiratory conditions. The RLF-100 compound is described as a synthetic form of human Vasoactive Intestinal Peptide (VIP), which is a ubiquitous, naturally synthesized human peptide.

Understanding the Science Behind RLF-100

The RLF-100 peptide, also known as aviptadil, is a synthetic version of Vasoactive Intestinal Peptide (VIP). VIP is a naturally occurring peptide hormone that plays a crucial role in various physiological processes, including smooth muscle relaxation, neurotransmission, and anti-inflammatory responses. In the context of respiratory diseases, VIP is known to have protective effects on lung tissue and can help to reduce inflammation and improve lung function.

Aviptadil (RLF 100) is a synthetic 28 amino acid vasoactive intestinal polypeptide (VIP) analogue. Its mechanism of action is thought to involve binding to VIP receptors on lung cells, which can lead to a cascade of beneficial effects, such as reducing inflammation, protecting alveolar epithelial cells, and promoting lung repair.

The development of RLF-100 has involved rigorous scientific investigation. RLF-100®(aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids. Research has focused on its stability, with promising initial stability findings reported, and positive 12-month stability data also released. The compound has been awarded FDA Fast Track designation for treating critical COVID-19 with Respiratory Failure, underscoring its potential to address unmet medical needs.

Key Entities and Terms Associated with RLF-100

* RLF-100: The primary search keyword, referring to the investigational drug.

* Aviptadil: The generic name for RLF-100.

* Vasoactive Intestinal Peptide (VIP): The natural human peptide that aviptadil is modeled after.

* Peptide: A short chain of amino acids, the building blocks of proteins.

* NeuroRx: A pharmaceutical company involved in the development of RLF-100.

* Relief Therapeutics: Another key pharmaceutical company in the development of RLF-100.

* Clinical Trials: Studies conducted to evaluate the safety and efficacy of drugs.

* Respiratory Failure: A life-threatening condition where the lungs cannot adequately oxygenate the blood